Le Lézard
Classified in: Health
Subject: FDA

Drawbridge Health Receives FDA 510(k) Clearance for OneDrawtm A1C Test System


MENLO PARK, Calif., Aug. 22, 2019 /PRNewswire/ -- Drawbridge Health today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the OneDrawtm A1C Test System, comprised of the OneDraw Blood Collection Device and the OneDraw A1C Test. The OneDraw A1C Test System is intended for the collection and stabilization of blood and measurement of HbA1c levels for monitoring the long-term control of blood sugar (glucose) in people with diabetes. The OneDraw A1C Test System enables blood to be drawn quickly, comfortably, and conveniently by a health care professional (HCP).

Drawbridge Health OneDrawtm A1C Test System

The OneDraw Blood Collection Device is a small, single-use device that draws, collects, and stabilizes a capillary blood sample from the upper arm. Instead of using a traditional hypodermic needle to puncture a patient's vein, the device is placed on the skin and blood is gently collected using tiny lancets with a light vacuum suction. The blood sample is then stabilized and contained within a removable cartridge, designed to protect the sample during transport. After the use of the OneDraw Blood Collection Device, the OneDraw A1C Test is performed by a designated certified clinical laboratory.

The OneDraw Blood Collection Device optimizes the blood collection process for both the patient and HCP and enables blood sampling to be performed anywhere. Drawbridge Health has balanced thoughtful design and proprietary technology to offer patients convenience, comfort, and peace of mind, particularly for patients suffering from the fear of needles. "Patients hate being stuck with needles and many will avoid important testing at all costs. Based on my experience, I believe my patients will be much more comfortable and relaxed ? minimal pain and they can't see the blood," comments Kristin Castorino, D.O., Sansum Diabetes Research Institute. Additionally, HCPs will benefit by streamlining the collection process, and ensuring patients complete their necessary blood work with results they can trust.

Drawbridge Health's 510(k) clearance follows the presentation of positive clinical data1 where study results indicated a strong correlation in the HbA1c measurement obtained from samples collected using the OneDraw Blood Collection Device and those using venipuncture. Moreover, the data showed a marked patient preference for the OneDraw Blood Collection device compared to venipuncture or fingerstick.

"Drawbridge Health was founded with the vision and intent to categorically and positively change the nature of blood-based diagnostic testing, improving both the collection process and patient experience," said Lee McCracken, CEO at Drawbridge Health. "Our 510(k) clearance is a critical milestone as we make our founding vision a reality. We look forward to making our novel technology commercially available soon."

1 Data presented at the 2019 ADA annual conference

About Drawbridge Health
Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood draw experience, enabling comfortable and convenient blood sample collection anytime and anywhere. By integrating engineering and proprietary chemistries, Drawbridge is developing a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit www.drawbridgehealth.com.

Contacts
PR Contact
Greg Nagy
gnagy@dbhealth.com

 

Drawbridge Health Logo (PRNewsfoto/Drawbridge Health)

SOURCE Drawbridge Health


These press releases may also interest you

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

at 10:10
Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral...

at 09:35
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019...

at 09:33
Oncopeptides AB  will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with...



News published on 22 august 2019 at 08:00 and distributed by: